Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
05 2021
Historique:
received: 15 05 2020
revised: 21 10 2020
accepted: 16 11 2020
pubmed: 5 12 2020
medline: 1 2 2022
entrez: 4 12 2020
Statut: ppublish

Résumé

Gallbladder cancer (GBC) is the most common type of biliary tract cancer, but the molecular mechanisms involved in gallbladder carcinogenesis remain poorly understood. In this study, we applied integrative genomics approaches to characterise GBC and explore molecular subtypes associated with patient survival. We profiled the mutational landscape of GBC tumours (whole-exome sequencing on 92, targeted sequencing on 98, in total 190 patients). In a subset (n = 45), we interrogated the matched transcriptomes, DNA methylomes, and somatic copy number alterations. We explored molecular subtypes identified through clustering tumours by genes whose expression was associated with survival in 47 tumours and validated subtypes on 34 publicly available GBC cases. Exome analysis revealed TP53 was the most mutated gene. The overall mutation rate was low (median 0.82 Mut/Mb). APOBEC-mediated mutational signatures were more common in tumours with higher mutational burden. Aflatoxin-related signatures tended to be highly clonal (present in ≥50% of cancer cells). Transcriptome-wide survival association analysis revealed a 95-gene signature that stratified all GBC patients into 3 subtypes that suggested an association with overall survival post-resection. The 2 poor-survival subtypes were associated with adverse clinicopathologic features (advanced stage, pN1, pM1), immunosuppressive micro-environments (myeloid-derived suppressor cell accumulation, extensive desmoplasia, hypoxia) and T cell dysfunction, whereas the good-survival subtype showed the opposite features. These data suggest that the tumour micro-environment and immune profiles could play an important role in gallbladder carcinogenesis and should be evaluated in future clinical studies, along with mutational profiles. Gallbladder cancer is highly fatal, and its causes are poorly understood. We evaluated gallbladder tumours to see if there were differences between tumours in genetic information such as DNA and RNA. We found evidence of aflatoxin exposure in these tumours, and immune cells surrounding the tumours were associated with survival.

Sections du résumé

BACKGROUND & AIMS
Gallbladder cancer (GBC) is the most common type of biliary tract cancer, but the molecular mechanisms involved in gallbladder carcinogenesis remain poorly understood. In this study, we applied integrative genomics approaches to characterise GBC and explore molecular subtypes associated with patient survival.
METHODS
We profiled the mutational landscape of GBC tumours (whole-exome sequencing on 92, targeted sequencing on 98, in total 190 patients). In a subset (n = 45), we interrogated the matched transcriptomes, DNA methylomes, and somatic copy number alterations. We explored molecular subtypes identified through clustering tumours by genes whose expression was associated with survival in 47 tumours and validated subtypes on 34 publicly available GBC cases.
RESULTS
Exome analysis revealed TP53 was the most mutated gene. The overall mutation rate was low (median 0.82 Mut/Mb). APOBEC-mediated mutational signatures were more common in tumours with higher mutational burden. Aflatoxin-related signatures tended to be highly clonal (present in ≥50% of cancer cells). Transcriptome-wide survival association analysis revealed a 95-gene signature that stratified all GBC patients into 3 subtypes that suggested an association with overall survival post-resection. The 2 poor-survival subtypes were associated with adverse clinicopathologic features (advanced stage, pN1, pM1), immunosuppressive micro-environments (myeloid-derived suppressor cell accumulation, extensive desmoplasia, hypoxia) and T cell dysfunction, whereas the good-survival subtype showed the opposite features.
CONCLUSION
These data suggest that the tumour micro-environment and immune profiles could play an important role in gallbladder carcinogenesis and should be evaluated in future clinical studies, along with mutational profiles.
LAY SUMMARY
Gallbladder cancer is highly fatal, and its causes are poorly understood. We evaluated gallbladder tumours to see if there were differences between tumours in genetic information such as DNA and RNA. We found evidence of aflatoxin exposure in these tumours, and immune cells surrounding the tumours were associated with survival.

Identifiants

pubmed: 33276026
pii: S0168-8278(20)33820-4
doi: 10.1016/j.jhep.2020.11.033
pmc: PMC8058239
mid: NIHMS1650925
pii:
doi:

Substances chimiques

Aflatoxins 0
Carcinogens 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1132-1144

Subventions

Organisme : Intramural NIH HHS
ID : ZIA CP010218
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Conflict of interest The authors have no relevant affiliation or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Nucleic Acids Res. 2019 Jan 8;47(D1):D994-D1004
pubmed: 30407583
Nat Rev Cancer. 2004 Sep;4(9):695-706
pubmed: 15343276
Nature. 2016 Sep 1;537(7618):63-68
pubmed: 27533040
Gastroenterology. 2017 Jul;153(1):249-262.e2
pubmed: 28363643
Ann Oncol. 2009 Jan;20(1):146-59
pubmed: 18667395
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
Gastroenterology. 2017 Aug;153(2):488-494.e1
pubmed: 28428144
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
Nat Genet. 2014 Aug;46(8):872-6
pubmed: 24997986
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
pubmed: 26787752
Br J Cancer. 2007 Dec 3;97(11):1577-82
pubmed: 18000509
Nat Genet. 2013 Dec;45(12):1470-1473
pubmed: 24185509
Cytokine. 2016 Jul;83:217-225
pubmed: 27173614
BMC Cancer. 2018 Mar 2;18(1):243
pubmed: 29499656
Tuberc Respir Dis (Seoul). 2016 Apr;79(2):85-90
pubmed: 27066085
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Mol Cancer. 2019 Oct 17;18(1):145
pubmed: 31623628
JAMA. 2015 May 26;313(20):2075-7
pubmed: 26010638
Biochim Biophys Acta. 2016 Apr;1865(2):245-54
pubmed: 26980625
Int J Cancer. 2010 Sep 1;127(5):1011-20
pubmed: 20017137
Int J Cancer. 2013 Oct 1;133(7):1664-71
pubmed: 23504585
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Nat Commun. 2019 Dec 2;10(1):5492
pubmed: 31792210
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Cancer. 2019 May 1;125(9):1489-1498
pubmed: 30645774
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Sci Rep. 2018 Apr 4;8(1):5671
pubmed: 29618736
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Cancer Med. 2016 Nov;5(11):3310-3235
pubmed: 27726295
Gut. 2019 Jun;68(6):1024-1033
pubmed: 29954840
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119

Auteurs

Chirag Nepal (C)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark.

Bin Zhu (B)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Colm J O'Rourke (CJ)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark.

Deepak Kumar Bhatt (DK)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark.

Donghyuk Lee (D)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Lei Song (L)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Difei Wang (D)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Alison L Van Dyke (AL)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Hyoyoung Choo-Wosoba (H)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Zhiwei Liu (Z)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Allan Hildesheim (A)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Alisa M Goldstein (AM)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Michael Dean (M)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Juan LaFuente-Barquero (J)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark.

Scott Lawrence (S)

Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Karun Mutreja (K)

Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Mary E Olanich (ME)

Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Justo Lorenzo Bermejo (J)

Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA; The CGR Exome Studies Group, NIH, Rockville, MD, USA.

Catterina Ferreccio (C)

Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; Advanced Center for Chronic Diseases (ACCDiS), FONDAP, Santiago, Chile.

Juan Carlos Roa (JC)

Department of Pathology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Asif Rashid (A)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ann W Hsing (AW)

Stanford Cancer Institute and Stanford Prevention Research Center, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA.

Yu-Tang Gao (YT)

Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.

Stephen J Chanock (SJ)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA.

Juan Carlos Araya (JC)

Advanced Center for Chronic Diseases (ACCDiS), FONDAP, Santiago, Chile; Hospital Dr. Hernán Henríquez Aravena, Temuco, Chile; Department of Pathology, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile.

Jesper B Andersen (JB)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: jesper.andersen@bric.ku.dk.

Jill Koshiol (J)

Division of Cancer Epidemiology and Genetics, NIH, Rockville, MD, USA. Electronic address: koshiolj@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH